to prevent migraine headaches in adults and adolescents 12 years and older
The consequence of obesity is not limited to the risk of developing cardiovascular diseases but also include the possibility of male fertility impairment (Figure 4)
In vivo, evidence from animal experiments also supports the role of excess copper in lipid metabolism
Price William John Price John E

The US FDA New Drug Approvals in May 2025 Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of May 2025 The US FDA has approved a total of 3 new drugs, including 2 new molecular entities and 1 Biologic leading to the treatment of patients and advances in the healthcare industry The major highlighted drug was AbbVies Emrelis securing FDA approval for treating NSCLC With High c-Met Protein Overexpression Company: Verastem Oncology Product: Avmapki + Fakzynja Active Ingredient: Avutometinib + Defactinib Disease: KRAS-Mutated Low-Grade Serous Ovarian Cancer Date: May 08, 2025 Shots: This accelerated approval for the combination of Avmapki (avutometinib) + Fakzynja (defactinib) was granted in advance to the planned PDUFA of Jun 30, 2025, which will be available in the US within a week as a co-pack Approval was based on P-II (RAMP 201) trial assessing Avmapki (3.2mg, twice weekly) + Fakzynja (200 mg, BID) in the above pts (n=57) dosed for first 3wks

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent- naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial